Inogen Stock Rises 47% in 6 Months: What's Driving the Rally?

Zacks10-04

Inogen, Inc. INGN has witnessed strong momentum in the past six months period. Shares of the company have surged 46.8% compared with 1.8% growth of the industry. The S&P 500 composite has risen 10% ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2473777964?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qBED1EE6lQoHDe7T4mhJTg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bbb2ede8f8cb3117fe54f0e6dc1c346c","is_english":true,"pubTime":"2024-10-04 22:54","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2473777964","market":"us","top_or_hot":-1,"title":"Inogen Stock Rises 47% in 6 Months: What's Driving the Rally?","media":"Zacks","content":"<div>\n<p>Inogen, Inc. INGN has witnessed strong momentum in the past six months period. Shares of the company have surged 46.8% compared with 1.8% growth of the industry. The S&P 500 composite has risen 10% ...</p>\n\n<a href=\"https://finance.yahoo.com/news/inogen-stock-rises-47-6-145400555.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Inogen Stock Rises 47% in 6 Months: What's Driving the Rally?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInogen Stock Rises 47% in 6 Months: What's Driving the Rally?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-04 22:54 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/inogen-stock-rises-47-6-145400555.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Inogen, Inc. INGN has witnessed strong momentum in the past six months period. Shares of the company have surged 46.8% compared with 1.8% growth of the industry. The S&P 500 composite has risen 10% ...</p>\n\n<a href=\"https://finance.yahoo.com/news/inogen-stock-rises-47-6-145400555.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0963586101.USD","symbol_name":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/inogen-stock-rises-47-6-145400555.html","article_id":"2473777964","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qBED1EE6lQoHDe7T4mhJTg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bbb2ede8f8cb3117fe54f0e6dc1c346c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2473777964","pubTimestamp":1728053640,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Inogen, Inc.INGN has witnessed strong momentum in the past six months period. Shares of the company have surged 46.8% compared with 1.8% growth of theindustry. The S&P 500 composite has risen 10% during the same time frame.With healthy fundamentals and strong growth opportunities, this Zacks Rank #2  company appears to be a solid wealth creator for its investors at the moment.Headquartered in Goleta, CA, Inogen develops, manufactures, and markets portable oxygen concentrators  used by patients who suffer from chronic respiratory conditions and need long-term oxygen therapy . POCs concentrate the air around the patient, filter out nitrogen and other unwanted substances, and deliver oxygen.Inogen’s products are marketed internationally through distributors and sold directly to patients and prescribers in the United States. The POC market is projected to rise from $1.58 billion in 2022 to $3.03 billion by 2030 at an 8.5% CAGR.Inogen's strategy focuses on targeting hospitals and individual","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","THC":"泰尼特","BK4196":"保健护理服务","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","INGN":"Inogen Inc","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","BK4539":"次新股","BK4082":"医疗保健设备","BK4185":"保健护理机构","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","AVAH":"Aveanna Healthcare Holdings Inc.","ATIP":"ATI Physical Therapy Inc."},"translate_title":"Inogen股价6个月内上涨47%：是什么推动了上涨？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATIP":1,"AVAH":1,"INGN":1,"THC":1},"content_text":"Inogen, Inc. INGN has witnessed strong momentum in the past six months period. Shares of the company have surged 46.8% compared with 1.8% growth of the industry. The S&P 500 composite has risen 10% during the same time frame.\nWith healthy fundamentals and strong growth opportunities, this Zacks Rank #2 (Buy) company appears to be a solid wealth creator for its investors at the moment.\nHeadquartered in Goleta, CA, Inogen develops, manufactures, and markets portable oxygen concentrators (POCs) used by patients who suffer from chronic respiratory conditions and need long-term oxygen therapy (LTOT). POCs concentrate the air around the patient, filter out nitrogen and other unwanted substances, and deliver oxygen.\nImage Source: Zacks Investment Research\nCatalysts Driving Growth\nHigh Prospects in the POC Space: Inogen is poised for growth due to its innovative POCs, which are superior to conventional oxygen therapy. The proprietary Inogen One and Inogen Rove systems provide supplemental oxygen anytime and anywhere, enhancing patient convenience.\nAs of Dec. 31, 2023, Inogen had 33 pending patent applications and 87 issued patents related to its respiratory devices, bolstered by the acquisition of Physio-Assist, which added more patents to its portfolio.\nInogen’s products are marketed internationally through distributors and sold directly to patients and prescribers in the United States. The POC market is projected to rise from $1.58 billion in 2022 to $3.03 billion by 2030 at an 8.5% CAGR.\nInogen sold 41,300 systems in the second quarter of 2024, a 21.1% increase year over year, and 75,200 systems in the first half of 2024, a 23.3% rise, which boosted stock performance.\nProduct Portfolio: Inogen's performance is enhanced by its expanding product portfolio, highlighted by the upcoming launch of Inogen Rove 4 in the third quarter of 2024, which received FDA 510(k) clearance in June. This model features a new flow setting, an eight-year service life and the highest oxygen production, making it the lightest POC on the market.\nAdditionally, Inogen Rove 6, launched in July 2023 in the United States, offers an eight-year service life. These advancements enhance Inogen’s competitive edge and growth potential in the POC market.\nInogen is focusing on research and development to enhance its oxygen therapy products and maintain market leadership. In the second quarter of 2024, R&D expenses rose 30.8% year over year, representing 6.3% of total revenues, primarily due to the Physio-Assist acquisition and increased product development costs, demonstrating the company’s commitment to innovation.\nStrong Q2 Results: Inogen's strong year-over-year growth in domestic and international business-to-business sales enhances optimism for the company. Solid revenues and profits, alongside an expanding adjusted gross margin, are encouraging.\nInogen's strategy focuses on targeting hospitals and individual practitioners via its rental business, improving patient access and extending payment duration. By enhancing scale and efficiency in this channel and reducing sales and marketing expenses post-exit from a third-party relationship, Inogen aims to boost profitability and enhance its stock outlook.\nRisk Factor\nStiff Competition: The LTOT market is highly competitive, with Inogen facing challenges from numerous manufacturers and distributors of POCs and other oxygen solutions. Major competitors include Respironics, Invacare and Resmed. As the regulatory path for oxygen therapy devices is relatively simple, Inogen anticipates heightened competition in the industry, which poses a risk for investors.\nA Look at Estimates\nThe Zacks Consensus Estimate for Inogen’s 2024 and 2025 bottom line projects a 56.6% and 13% year-over-year improvement, respectively, to a loss of $1.92 and $1.67 per share.\nIn the past 30 days, the Zacks Consensus Estimate for the company's 2024 loss has remained unchanged at $1.92 per share.\nRevenues for 2024 and 2025 are anticipated to rise 3.6% and 3.8%, respectively, to $326.98 million and $339.53 million on a year-over-year basis.\n\nInogen, Inc Price\n\nInogen, Inc price | Inogen, Inc Quote\n\nOther Key Picks\nSome other top-ranked stocks in the broader medical space are Tenet HealthCare (THC), ATI Physical Therapy (ATIP) and Aveanna Healthcare AVAH. While Tenet HealthCare carries a Zacks Rank #1 (Strong Buy), ATI Physical Therapy and Aveanna Healthcare carry a Zacks Rank #2 each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nTenet HealthCare has an estimated long-term growth rate of 18.3%. THC's earnings surpassed estimates in each of the trailing four quarters, with the average being 58.5%.\nTenet HealthCare has gained 119.9% compared with the industry's 48.6% growth year to date.\nATI Physical Therapy's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.25%.\nATIP's shares have gained 5.5% year to date compared with the industry’s 18.6% growth.\nAveanna Healthcare's earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 47.5%.\nAVAH's shares have surged 104.5% year to date compared with the industry’s 15.7% growth.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nTenet Healthcare Corporation (THC) : Free Stock Analysis Report\nInogen, Inc (INGN) : Free Stock Analysis Report\nAveanna Healthcare Holdings Inc. (AVAH) : Free Stock Analysis Report\nATI Physical Therapy, Inc. (ATIP) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473777964"}